Data from multiple sources - Curated by Toby Galbraith - Last updated 06 June 2017

Latest news articles

Added 2 days ago Drug news

NICE recommends Opdivo to treat head and neck cancer.- BMS.

When the National Institute for Health and Care Excellence (NICE) first reviewed Opdivo (nivolumab), it found that the evidence for...

Added 2 days ago Drug news

FDA approves Yescarta to treat large B-cell lymphoma.- Kite/Gilead Sciences.

Kite, a Gilead Company, announced that the FDA has granted regular approval to Yescarta (axicabtagene ciloleucel), the first chimeric antigen...

Added 2 days ago Drug news

Positive results from Keynote 024 trial for Keytruda for NSCLC.- Merck Inc.

Merck announced the presentation of updated overall survival (OS) findings, a secondary endpoint, from the phase III KEYNOTE-024 trial evaluating...

Search all news articles for Oncology
 

 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Breakthrough Cancer Pain Learning Zone

Invitation to watch the online broadcast of the BeCOn OWN event 'Shifting paradigms in BTcP management' on June 16 2017.

Visit Breakthrough Cancer Pain Learning Zone

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

Visit Chronic Lymphocytic Leukaemia (CLL)

Cushing's Syndrome

Cushing’s syndrome shares symptoms such as hypertension, glucose intolerance and obesity with other common conditions – how can you confidently diagnose this rare disorder?

Visit Cushing's Syndrome

What's on the horizon?

Marshall Pearce

Antibody-drug conjugates (ADCs)

Over the past couple of decades, there have been advances in a class of drugs which for a long time was purely theoretical: antibody-drug conjugates (ADCs). The concept underlying ADCs is elegant – what if it were possible to ‘target’ particular groups of cells with a cytotoxic agent, rather than exposing every cell of the body to it?

Marshall Pearce

Cancer immunotherapies

It was the winner of the 1908 Nobel prize for medicine, Paul Ehrlich, who is first credited with discussing the concept of a “magic bullet”, able to target specific cells without damaging healthy tissue. With the advent of immunotherapy, as well as antibody-drug conjugates, we are beginning to realise this vision.

Guidelines

Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Evidence shows that rectal cancer is distinct from colon cancer, with different aetiologies and risk factors possibly reflecting different environmental exposures.

Added 4 years ago

Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Cervical cancer is the second most commonly diagnosed cancer and the third leading cause of cancer death among females in less developed countries. These updated guidelines focus on the management...

Added 5 years ago

Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Mantle cell lymphoma is a relatively uncommon subtype of lymphoid malignancy and is more often found in males than in females. These updated ESMO guidelines provide treatment recommendations...

Added 3 years ago

Search all guidelines for Oncology
 

Journal articles

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.

Background: Merkel cell carcinoma is a rare, aggressive skin cancer with poor prognosis in patients with advanced disease. Current standard care uses various cytotoxic chemotherapy regimens...

Added 4 days ago

Plerixafor injection: a hematopoietic stem cell mobilizer in non-Hodgkin lymphoma and multiple myeloma.

Introduction: A combination of granulocyte colony-stimulating factor (G-CSF) and chemotherapy or G-CSF alone are the most common mobilization regimens for autotransplantations.

Added 5 days ago

Plerixafor for stem cell mobilization: the current status.

Purpose of review: Nowadays, plerixafor is approved for patients who fail to mobilize sufficient CD34⁺ cells for an autologous stem cell transplantation. Plerixafor is effective in the majority of these patients...

Added 5 days ago

Search all journal articles for Oncology
 

Clinical trials

Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma

This study involves a course of radiation to up to 5 tumors in the participant's liver followed by systemic therapy (Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body).

Added 6 months ago

A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy (OAK)

This global, multicenter, open-label, randomized, controlled study will evaluate the efficacy and safety of atezolizumab (an anti-programmed death−ligand 1 [anti-PD-L1] antibody) compared with docetaxel...

Added 19 days ago

Study of abiraterone acetate plus ADT versus apalatumide versus abiraterone and apalatumide in patients with advanced prostate cancer with non-castrate testosterone levels

Evaluation of the activity, safety and patients reported outcome of ADT plus abiraterone, abiraterone plus APALUTAMIDE (a second-generation antiandrogen) or APALUTAMIDE alone in hormone naïve locally advanced...

Added 1 year ago

Search all clinical trials for Oncology
 

Blog Posts

Fiona Holland

What to say and do when someone has cancer

Posted 8 months ago

Ahead of World Cancer Day on Saturday (February 4), Fiona Holland, Psychology Lecturer, discusses what to say and what not to say to someone with cancer.

Hugh Harvey

Metrics Madness

Posted 2 years ago

You shouldn't judge a book by its cover. That much is true, but it's also common sense not to judge a book by measuring the whiteness of its pages, or the amount of hamsters you can place on it. So why do we measure the fabulous NHS with nonsense metrics?

CME

Treatment Optimisation in Chronic Lymphocytic Leukaemia

Treatment Optimisation in Chronic Lymphocytic Leukaemia
Accrediting body
Union of European Medical Specialists (via European Accreditation Council for CME)
Credits available
1
Registration required
1
Subscription fee
FREE

Managing the side effects of treatment for prostate cancer

Accrediting body
BMJ Learning - British Medical Learning
Credits available
1
Registration required
1
Subscription fee
90

Managing patients at risk of prostate cancer

Accrediting body
BMJ Learning - British Medical Learning
Credits available
1
Registration required
1
Subscription fee
90
Search all CME for Oncology